Log in to search using one of your social media accounts:

 

Janssen reports positive results from Phase III darunavir-based HIV regimen trial
Janssen-Cilag International has reported positive results from a Phase III clinical trial (EMERALD) of darunavir containing a single-tablet regimen (STR) in patients with human immunodeficiency virus type 1 (HIV-1). (Source: Drug Development Technology)
Source: Drug Development Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news

Janssen Receives Positive CHMP Opinion for SYMTUZA ™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
- Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet (Source: Johnson and Johnson)
Source: Johnson and Johnson - July 21, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet Regimen
First in-human, Phase 1/2a data from APPROACH preventive HIV-1 vaccine clinical trial to be featured in oral presentation and included in official IAS press program. Interim results from the Phase 3 pivotal EMERALD trial investigating darunavir-based single-tablet regimen selected for oral presentation; data submitted to regulatory authorities for EMA approval, September 2017. (Source: Johnson and Johnson)
Source: Johnson and Johnson - July 12, 2017 Category: Pharmaceuticals Source Type: news

Switching From ATV or LPV to DRV Improves Kidney Function Switching From ATV or LPV to DRV Improves Kidney Function
HIV patients who switched their protease inhibitor to darunavir realized an improvement in renal function.AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2017 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Darunavir Linked to Heightened Heart Disease Risk Darunavir Linked to Heightened Heart Disease Risk
The early protease inhibitors are known to increase risk for heart attack, stroke, and sudden cardiac death. Now, data from the D:A:D study raise concerns about next-generation drugs.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 17, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Darunavir Associated with Heart Disease (CME/CE)
(MedPage Today) -- But atazanavir use in HIV patients not linked to cardiovascular disease (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 17, 2017 Category: Cardiology Source Type: news

Merck ’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Dateline City: KENILWORTH, N.J. Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-na ïve Adults after 48 weeks of TreatmentKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI).Language: EnglishContact: MerckMedia:Doris Li, 908-246-5701Carmen de Gourville, 267-664-0146orInvestors:Teri Loxam, 908-740-198...
Source: Merck.com - Research and Development News - February 14, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Doravirine HIV MSD NYSE:MRK Source Type: news

Efficacy of DRV/r Monotherapy vs DRV/r With Two NRTIs Efficacy of DRV/r Monotherapy vs DRV/r With Two NRTIs
How does darunavir/ritonavir monotherapy compare with DRV/r-based triple ART in terms of efficacy and safety?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 11, 2017 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Prezcobix (Darunavir and Cobicistat Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 14, 2016 Category: Drugs & Pharmacology Source Type: news

Darunavir/Ritonavir in HIV-1-Infected Pregnant Women Darunavir/Ritonavir in HIV-1-Infected Pregnant Women
How does pregnancy affect the pharmacokinetics of this antiretroviral regimen?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 9, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

A Study of DRV/r for HIV Post-Exposure Prophylaxis A Study of DRV/r for HIV Post-Exposure Prophylaxis
Should ritonavir-boosted darunavir be considered as part of a HIV post-exposure prophylaxis regimen?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 4, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

FDA Clears Darunavir (Prezista) for Pregnant Women With HIV FDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news

FDA Clears Darunavir (Prezista) for Pregnant Women With HIVFDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news

U.S. FDA Approves Prezista (darunavir) for Use in Pregnant Women with HIV
TITUSVILLE, N.J., July 18, 2016 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion to the Prezista (darunavir) U.S. Prescribing... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 18, 2016 Category: Drugs & Pharmacology Source Type: news

Prezista (Darunavir) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 30, 2016 Category: Drugs & Pharmacology Source Type: news

Darunavir Plus Cobicistat Works Well in Older HIV Groups (CME/CE)
(MedPage Today) -- Agent to boost protease inhibitor drugs seems safe, effective in older patients (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - June 22, 2016 Category: Infectious Diseases Source Type: news

NRTI Sparing Therapy in Virologically Controlled HIVNRTI Sparing Therapy in Virologically Controlled HIV
This study explores the combination of rilpivirine plus boosted darunavir as an option when switching from standard cART in patients who are virologically suppressed. JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 1, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Importantes interacciones entre el medicamento Victrelis (boceprevir) y los medicamentos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir
El 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud y a los pacientes que la interacción entre Victrelis (boceprevir), un medicamento inhibidor de la proteasa del virus de hepatitis C (VHC), y ciertos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir (atazanavir, lopinavir, darunavir) tiene el potencial de reducir la eficacia de dichos medicamentos cuando se usan conjuntamente (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Prezcobix (Darunavir and Cobicistat Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Janssen Embraces Continuous Manufacturing for Prezista
Strategy seeks CM’s well-researched savings and efficiencies for its Gurabo, Puerto Rico, plant (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 8, 2015 Category: Pharmaceuticals Source Type: news

Darunavir and Trimethoprim-Sulfamethoxazole Cross-ReactivityDarunavir and Trimethoprim-Sulfamethoxazole Cross-Reactivity
This study examines the cross-reactivity between both drugs. AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 25, 2015 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Prezcobix™ (darunavir / cobicistat) for the Treatment of HIV-1
Prezcobix™ (darunavir / cobicistat), discovered and developed by Janssen Therapeutics, is a fixed-dose antiretroviral combination tablet indicated for the treatment of human immunodeficiency virus (HIV-1) infection. (Source: Drug Development Technology)
Source: Drug Development Technology - May 13, 2015 Category: Pharmaceuticals Source Type: news

Africa: Johnson & Johnson Expands Ip Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living With HIV
[PR Newswire] Raritan, New Jersey -Expanded Policy will Increase Access for Darunavir Pediatric Formulations in 128 Resource-Limited Countries (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - May 12, 2015 Category: Infectious Diseases Source Type: news

Dolutegravir Remains Superior to Boosted Darunavir for HIV-1Dolutegravir Remains Superior to Boosted Darunavir for HIV-1
Once-daily dolutegravir maintains its higher virological response rates over those of ritonavir-boosted darunavir in treatment-naïve adults with HIV-1 infection, according to 96-week results from the FLAMINGO study. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2015 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDADarunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA
The fixed-dose combination of the antiretroviral drug darunavir (800 mg) and the pharmacokinetic enhancer cobicistat (150 mg) is for adults with HIV-1 infection and no darunavir resistance mutations. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2015 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

FDA Approves Two Medications to Treat HIV Infection: Evotaz and Prezcobix
On January 29, 2015, FDA sent e-mails noting the approval of two HIV medications to treat HIV infection:   "On January 29, 2015, FDA approved Evotaz, a fixed dose combination tablet containing 300 mg of atazanavir and 150 mg of cobicistat. Evotaz is indicated in combination with other antiretroviral agents for the treatment of … human immunodeficiency virus (HIV 1) infection in adults."   "On January 29, 2015, FDA approved Prezcobix a fixed dose combination tablet containing 800 mg of darunavir and 150 mg of cobicistat.   "Prezcobix is indicated in combination with other antiretrov...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 30, 2015 Category: Infectious Diseases Source Type: news

Lupin gets USFDA nod for HIV drug
Drug firm Lupin has received tentative approval from the US health regulator to market a generic version of Prezista tablets, used in treating HIV infection. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 30, 2014 Category: Pharmaceuticals Source Type: news

Reduced Darunavir Dose Maintains HIV SuppressionReduced Darunavir Dose Maintains HIV Suppression
A 600-mg dose of darunavir is as effective as the approved 800-mg dose in maintaining HIV suppression, researchers from Spain report. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2014 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

View AIDSinfo Patient Fact Sheets on Three Recently Approved HIV Medications
AIDSinfo invites you to view our patient fact sheets on three medications recently approved by the FDA. The three medications are all indicated for use in the treatment of HIV infection in adults. The patient fact sheets include information on dosage forms and strengths, possible side effects, and instructions on how to take and store the medications. Fact sheet on abacavir/dolutegravir/lamivudine (brand name: Triumeq) Triumeq is a combination medicine that can be used alone as a complete treatment regimen or with other HIV medicines. Fact sheet on cobicistat (brand name: Tybost) Cobicistat is a pharmacoki...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 24, 2014 Category: Infectious Diseases Source Type: news

EMA Panel Endorses Darunavir/Cobicistat Combo for HIVEMA Panel Endorses Darunavir/Cobicistat Combo for HIV
Rezolsta is intended for the treatment of antiretroviral therapy-naive and antiretroviral therapy-experienced adults with no darunavir-resistance-associated mutations. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 29, 2014 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

FDA Approves Two Medications to Treat HIV Infection: Cobicistat (Brand Name: Tybost) and Elvitegravir (Brand Name: Vitekta)
"On September 24, 2014, FDA approved Tybost (cobicistat) 150 mg tablets. Tybost is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection." For more information on cobicistat, view the FDA press release. "On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets. Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor coadministered with ritonavir an...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 26, 2014 Category: Infectious Diseases Source Type: news

FDA Updates Etravirine Labeling
"On August 20, 2014, the Intelence (etravirine) label was updated to include information regarding coadministration of etravirine with the following drugs: "dolutegravir, dolutegravir/darunavir/ritonavir, dolutegravir/lopinavir/ritonavir "atazanavir/ritonavir "boceprevir" The updated labeling for etravirine is available at the FDA website. More information is available: FDA: Press release AIDSinfo: Patient fact sheet on etravirine (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 29, 2014 Category: Infectious Diseases Source Type: news

ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1
An investigational two drug-regimen of maraviroc dosed once daily, combined with darunavir/ritonavir (DRV/r) showed inferior efficacy compared to emtricitabine/tenofovir (FTC/TDF) with DRV/r. (Source: GSK news)
Source: GSK news - July 22, 2014 Category: Pharmaceuticals Source Type: news

FDA Updates Darunavir (Prezista) Labeling
“On April 7, 2014, FDA approved new changes to the Prezista (darunavir) label to update the following sections: “WARNING AND PRECAUTIONS, Severe Skin Reactions,  ADVERSE REACTIONS, Postmarketing Experience, and PATIENT COUNSELING INFORMATION sections of the labeling were updated with information regarding rash with eosinophilia and systemic symptoms. “DRUG INTERACTIONS, Established and Other Potentially Significant Drug Interaction and CLINICAL PHARMACOLOGY, Table 15 subsections of the labeling were updated with information regarding dolutegravir. … “CLINICAL PHARMACOLOGY, Microbi...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 11, 2014 Category: Infectious Diseases Source Type: news

Janssen Files NDA For New HIV Combo Drug
Janssen Research & Development (Janssen) announced that it has filed a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose antiretroviral combination tablet containing its protease inhibitor Prezista (darunavir) with Gilead Sciences’ cobicistat, an investigational pharmacokinetic enhancer for use in combination with other human immunodeficiency virus (HIV-1) medicines. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 3, 2014 Category: Pharmaceuticals Source Type: news

Raltegravir Combo Gives New Anti-HIV Alternative
BOSTON (MedPage Today) -- The use of a two-drug anti-HIV therapy of raltegravir (Isentress) plus darunavir (Prezista) appeared to be non-inferior to tenofovir/emtricitabine (Truvada) plus darunavir, researchers reported here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - March 6, 2014 Category: Consumer Health News Source Type: news

New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today that in a new 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-naïve patients – one containing Merck’s twice-daily ISENTRESS® (raltegravir) and two containing different once-daily ritonavir-boosted protease inhibitors, atazanavir and darunavir -- all three regimens achieved high and equivalent levels of efficacy, as measured by time t...
Source: Merck.com - Research and Development News - March 5, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today that in a new 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-naïve patients – one containing Merck’s twice-daily ISENTRESS® (raltegravir) and two containing different once-daily ritonavir-boosted protease inhibitors, atazanavir and darunavir -- all three regimens achieved high and equivalent levels of efficacy, as measured by time to...
Source: Merck.com - Product News - March 5, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Janssen seeks EMA approval for fixed-dose combination of HIV medicine darunavir with cobicistat
Janssen-Cilag (Janssen), a subsidiary of the Johnson & Johnson pharmaceutical firm, has filed a marketing authorisation application with the European Medicines Agency (EMA) for the approval of a once-daily fixed-dose antiretroviral combination tablet… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 15, 2013 Category: Pharmaceuticals Source Type: news

Dolutegravir vs Darunavir: Positive Data From FLAMINGODolutegravir vs Darunavir: Positive Data From FLAMINGO
Dr. Paul Sax discusses results of the FLAMINGO study comparing dolutegravir vs ritonavir-boosted darunavir in treatment-naive patients with HIV. Medscape HIV/AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2013 Category: Consumer Health News Tags: HIV/AIDS Commentary Source Type: news

New HIV Drug Matches Old Standard (CME/CE)
DENVER (MedPage Today) -- The recently approved anti-HIV medication dolutegravir (Tivicay) has equivalent efficacy to boosted darunavir (Prezista), a researcher said. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 13, 2013 Category: Consumer Health News Source Type: news

ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1
ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. (Source: GSK news)
Source: GSK news - September 12, 2013 Category: Pharmaceuticals Source Type: news

Prezista Extends HIV Suppression in Children (CME/CE)
KUALA LUMPUR (MedPage Today) -- Children with human immunodeficiency virus (HIV) maintain viral control over 48 weeks when treated with the protease inhibitor darunavir/ritonavir (Prezista) along with an optimized background regimen, researchers reported here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 6, 2013 Category: Consumer Health News Source Type: news

Generic Competition Pushing Down HIV Drug Prices, But Patents Keep Newer Drugs Unaffordable
Myanmar 2012 © Greg Constantine A patient collects her medication from the pharmacy at an MSF clinic in Yangon, where MSF treats HIV/AIDS and TB. Report Download Report [2.05 MB] Report Download Report [4.86 MB] KUALA LUMPUR/NEW YORK, JULY 2, 2013—The price of first- and second-line antiretrovirals (ARVs) to treat HIV are falling because of increased competition among generic producers, but newer ARVs continue to be priced astronomically high, according to the annual report Untangling the Web of ARV Price Reductions, released today by the international medical humanitarian orga...
Source: MSF News - July 3, 2013 Category: Global & Universal Source Type: news

Recent HIV/AIDS News
April 30, 2013: U.S. Preventive Services Task Force Issues Final Recommendation Statement on Screening for HIV “The U.S. Preventive Services Task Force (Task Force) today released its final recommendation statement on screening for HIV. The Task Force recommends that clinicians screen all people aged 15 to 65, as well as younger adolescents and older adults who are at an increased risk for HIV infection.” Read the AIDS.gov blog post.   April 25, 2013: Prezista (Darunavir) Labeling Changes “On April 24, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspens...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 3, 2013 Category: Infectious Diseases Source Type: news

Recent News from NIH and FDA
NIH-sponsored researchers announced the following news at the Conference on Retroviruses and Opportunistic Infections (CROI) this week: March 4, 2013: Daily-Use HIV Prevention Approaches Prove Ineffective Among Women in NIH Study “Three antiretroviral-based strategies intended to prevent HIV infection among women did not prove effective in a major clinical trial in Africa.” Read the NIH press release.   March 3, 2013: Toddler ‘Functionally Cured’ of HIV Infection, NIH-Supported Investigators Report “A two-year-old child born with HIV infection and treated with a...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 5, 2013 Category: Infectious Diseases Source Type: news

Correction to the Perinatal Guidelines Issued
On April 3, 2013, an error in the references in the Darunavir section was corrected. Reference 4 was updated. To view the correction notice, please click here. (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 5, 2013 Category: Infectious Diseases Source Type: news

FDA Updates Darunavir Tablet and Oral Suspension Labeling with Pediatric Dosing Information
“On February 1, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to include once daily dosing in treatment-naïve subjects 3 to less than 18 years of age and once daily dosing in treatment-experienced subjects 3 to less than 18 years of age with no darunavir resistance associated substitutions.” The updated labeling will be available at the FDA website. More information is available: FDA: Press release AIDSinfo: Darunavir (Prezista) patient drug summary (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Servi...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 7, 2013 Category: Infectious Diseases Source Type: news

HIV/AIDS Update - Prezista (darunavir) tablet and oral suspension: pediatric dosing
On February 1, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to include once daily dosing in treatment-naïve subjects 3 to less than 18 years of age and once daily dosing in treatment-experienced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 4, 2013 Category: Pharmaceuticals Source Type: news

European Commission Approves PREZISTA® (Darunavir) 800mg Tablet Once A Day Reducing The Number Of Pills Taken By People Living With HIV
Janssen R&D Ireland has announced that the European Commission (EC) has approved a new PREZISTA(R) (darunavir) 800mg tablet allowing people living with HIV to take one darunavir tablet once a day. Darunavir is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced and treatment-naive patients with no darunavir resistance-associated mutations[i].[1] Darunavir is always taken in combination with ritonavir and other HIV medicines together with food... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 17, 2013 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news